January 2026

Week in Review: Abbott exec plans exit | IVL competition heats up | ASNC favors PET | Medtech companies speak out | AI for POCUS ()
Faster treatments, better outcomes | Robotic heart surgery gains momentum | Cath lab strategies | TAVR's next challenge ()
Tap water linked to potential risks | New cardiac care certification announced | FDA clears AI software | Post-stroke injections ()
ASNC chooses PET | Comparing OBLs & ASCs | TMVR device gains approval | The risks of HF | Paradoxical low-flow, low gradient AS ()
Key takeaways from new stroke guideline | The fight over certification | AI for POCUS | A PET trend to watch | Abbott VP to exit ()
Cath labs work to stay ahead | Feedback rolls in as CMS considers TAVR changes | FDA approves new stent for deep venous disease ()
Minnesota companies speak out | Exploring IVL trends | Robotic cardiac surgery building momentum | Cannabis & patient outcomes ()
IVL competition heats up | Medtronic's new PFA approval | 2 important trials set to begin | Surgeon pleads not guilty to murder ()
Week in Review: Recalled CGM sensors lead to lawsuit | Vascular surgeon indicted for murder | Tracking radiation in the cath lab ()
FDA approves TMVR system for high-risk patients | Abbott reports climbing medtech sales | CMS considering major policy changes ()
Medtronic invests $90M in TAVR company | Radiation in the cath lab | Abbott’s medtech sales climb | PFA system impresses ()
The importance of heart failure prevention | New-look therapy shows promise | Updated statistics on U.S. heart health ()
AI calls cath lab patients | Mediterranean diet protects the heart | Atherectomy & CLTI | J&J's earnings | Abbott's new partner ()
FDA stays busy with AI clearances | Aetna updates coverage policy | Flagging hard-to-detect heart disease in seconds ()
Feedback rolls in as CMS considers sweeping TAVR changes | Improving care in cardiology deserts | Abbott gains key approval ()
New heart failure treatment shows promise | Vascular surgeon indicted for murder | Carotid stent impresses | SVD after TAVR ()
Improved payments for OBLs & ASCs | Boston Scientific to acquire Penumbra | Medtronic’s diabetes spin-off files for IPO ()
Patient files lawsuit over recall | Heart teams playing a major role | Abbott TAVR valve impresses | Preventing heart failure ()
Top 10 most popular cardiology video interviews this past month ()
Week in Review: Supplements recalled | Judge blocks JenaValve acquisition | Boston Scientific to acquire Penumbra ()
IVL's future | Endovascular grafts recalled | The business of cardiology is changing | Cath lab strategies | Workforce concerns ()
Boston Scientific inks deal worth $14.5B | FDA clears opportunistic AI | TAVR’s next big challenge | Good news for OBLs & ASCs ()
News Alert: Boston Scientific to acquire Penumbra for $14.5B ()
FDA clears MRI-compatible catheter | A new radiotracer shortage | TAVR & M-TEER outcomes | Rape charges against doctor dropped ()
FDA confirms recall after device left in patient’s body | Bleeding reversal agent pulled from market | ACC & AHA take on PAD ()
Key trends in cardiovascular health | FDA approves PFA catheter | Bayer makes a move | Medtech company acquired | CCTA education ()
CCTA making an impact | Cardiology's biggest trend | Recall confirmed | Philips, Bayer announce new deals | Positron raises $2M ()
‘Mental clarity’ supplement recalled | New data on SDD after PCI | FDA clears diabetes tech | Stroke on plane leads to lawsuit ()
FDA approves nasal spray for abnormal heart rhythms | Abbott's big news | CBD shows potential | AI powers new PFA registry ()
JenaValve acquisition blocked | Cath labs keeping up with changes | A new PAD resource | Supplement recalled | RSNA seeks editor ()
Week in Review: Trump's heart health | FDA announces multiple recalls | Positron raises $2M | IVL's future | CBD & heart disease ()
IVL in diabetic patients | CBD shows potential to treat heart disease | Trump regrets heart exam | Big news for MiniMed ()
CCTA transforming care | FDA clears AI platform | A new way to prevent coronary obstruction after TAVR | PE-backed group grows ()
CBD & heart disease | ASE's top priorities | Cardiologist reinstated | Progress for sublingual heart drug | FDA's AI decision ()
TAVR Highlights: CMS considers expanded coverage | Treating severe AS in cancer patients | Market factors impacting decisions ()
The future of IVL | Aetna's big coverage decision | Cardiology pioneer dies at 91 | FDA approves 2 devices | TAVR & cancer ()
Surgeons tweak ‘frozen elephant trunk’ technique | 3 key recalls | Outside forces influencing TAVR/SAVR decisions ()
FDA confirms new recall | Medtech company acquired | Trump's aspirin use | Positron raises $2M | A key approval for Edwards ()
Key Interviews from 2025: Questions remain about PFA's value | EARLY TAVR concerns | Medicare covers TriClip | Much more ()
Endovascular grafts recalled due to safety risk | FDA confirms recalls for J&J, Medtronic | ASE looks back at a busy year ()
Top Cardiology Video Interviews in 2025 ()
2025 in Review: Recalls, lawsuits & the best heart hospitals in the United States ()